-- 瑞銀表示,加拿大政府週二發布了春季經濟展望報告,將2025-26財年的財政赤字預測值下調約20億加元至約670億加元,約佔國內生產總值(GDP)的2.1%,低於先前預測的2.5%。 瑞銀在致客戶的報告中指出,這意味著赤字佔GDP的比重將比2024-25財年擴大0.9個百分點,預計2026-27財年和2027-28財年的赤字佔GDP的比重將分別維持在1.9%和1.8%。 瑞銀表示,2025-26財年赤字前景的改善反映了經濟成長和收入因油價上漲而增加,同時也反映了對未來幾年多項計畫預期實施情況的重新評估。 這包括修訂自然災害負債準備金,以及修訂清潔經濟投資稅收抵免和電動車電池製造補助的實施時間。 由於預期支出成長放緩,瑞銀將本財年財政支持預期下調了十分之一,並略微增加了對明年和2028年的預期。因此,瑞銀對今年實際GDP成長的預期為1.5%,2027年為1.7%,2028年為1.8%。 自2025年預算案發布以來,並納入春季經濟更新,預計未來六年財政支出將達到約550億加元,其中約380億加元來自本週的更新。 新增支出的大部分是未來三年約250億加元的現金支出,用於啟動加拿大主權財富基金——「加拿大強大基金」——以及約60億加元用於提升年輕工人的技能和支持住房供應。
Related Articles
Sector Update: Financial
Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.
Market Chatter: Zuckerberg, Cook Not Exploring Seattle Seahawks Bid
Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%
Axsome Therapeutics Says FDA Approves Auvelity for Alzheimer's Disease Agitation
Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%